You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK)附屬治療多發性骨髓瘤藥物 研究更新總緩解率為98%
阿思達克 05-28 12:37
金斯瑞生物科技(01548.HK)公布,非全資附屬傳奇生物科技2021年美國臨床腫瘤學會(ASCO)年會和歐洲血液學協會(EHA)線上虛擬大會上,公佈關於靶向B細胞成熟抗原(BCMA)的嵌合抗原受體T細胞(CAR-T)療法西達基奧侖賽Ciltacabtagene Autoleucel(cilta-cel)的最新及更新結果,該療法用於治療復發和╱或難治性多發性骨髓瘤(RRMM)。

CARTITUDE-1 1b/2期研究的更新結果(其中包括97位經過大量前期治療的患者)顯示,18個月中位隨訪的總緩解率(ORR)為98%,其中80%的患者達到嚴格意義的完全緩解(sCR)突顯出隨著時間推移緩解不斷加深(ASH 2020公佈資料為67%)。18個月無進展生存(PFS)率為66%(95%置信區間CI,54.9–75.0),總生存率(OS)為81%(95%CI,71.4–87.6)。患者之前接受了中位數六線治療(範圍3–18);其中88%的患者三重耐藥,42%的患者五重耐藥。對於預先指定的各亞組,緩解率具有可比性(範圍90–100%),包括先前治療線數,髓外漿細胞瘤和細胞遺傳學風險方面。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account